Related references
Note: Only part of the references are listed.Systemic chemotherapy and new experimental approaches in the treatment of metastatic prostate cancer
C. N. Sternberg
ANNALS OF ONCOLOGY (2008)
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival in the TAX 327 study
Dominik R. Berthold et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the prostate cancer clinical trials working group
Howard I. Scher et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Adjuvant chemotherapy followed by Goserelin compared with either modality alone:: The impact on amenorrhea, hot flashes, and quality of life in premenopausal patients -: The International Breast Cancer Study Group trial VIII
Juerg Bernhard et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Response to second-line chemotherapy in patients with hormone refractory prostate cancer receiving two sequences of mitoxantrone and taxanes
William K. Oh et al.
UROLOGY (2006)
Modulation of the cellular pharmacology of JM118, the major metabolite of satraplatin, by copper influx and efflux transporters
G Samimi et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2006)
Management of advanced prostate cancer after first-line chemotherapy
DR Berthold et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Satraplatin in the treatment of hormone-refractory prostate cancer
CN Sternberg
BJU INTERNATIONAL (2005)
Phase II study of oral bis (aceto) ammine dichloro (cyclohexamine) platinum (IV) (JM-216, BMS-182751) given daily x 5 in hormone refractory prostate cancer (HRPC)
T Latif et al.
INVESTIGATIONAL NEW DRUGS (2005)
Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer
CN Sternberg et al.
ONCOLOGY (2005)
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer
DP Petrylak et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
IF Tannock et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
What's new in the treatment of advanced prostate cancer?
CN Sternberg
EUROPEAN JOURNAL OF CANCER (2003)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
